Alexion’s $569,000 Drug Draws Data Demand From U.K. NICE
This article is for subscribers only.
Alexion Pharmaceuticals Inc. should provide information on research and manufacturing costs for its Soliris rare-disease drug to help justify a price of 340,200 pounds a year ($569,000), the U.K.’s health-cost agency said.
The drug, also known as eculizumab, is an effective treatment for a blood disorder known as atypical hemolytic uremic syndrome, the National Institute for Health and Care Excellence said in an e-mailed statement. Still, the product will cost the National Health Service about 58 million pounds in the first year of treatment, rising to more than 80 million pounds in five years, the institute said.